Immunotherapy combination approaches: mechanisms, biomarkers and clinical observations.
Butterfield LH, Najjar YG.
Nat Rev Immunol. 2024 Jun;24(6):399-416. doi: 10.1038/s41577-023-00973-8. Epub 2023 Dec 6.
Photodynamic and Photothermal Therapies: Synergy Opportunities for Nanomedicine.
Overchuk M, Weersink RA, Wilson BC, Zheng G.
ACS Nano. 2023 May 9;17(9):7979-8003. doi: 10.1021/acsnano.3c00891. Epub 2023 Apr 27.
Immunotherapy for the treatment of multiple myeloma.
Boussi LS, Avigan ZM, Rosenblatt J.
Front Immunol. 2022 Oct 28;13:1027385. doi: 10.3389/fimmu.2022.1027385. eCollection 2022.
Effect of Water Exercise Therapy on Lower Limb Function Rehabilitation in Hemiplegic Patients with the First Stroke.
Bei N, Long D, Bei Z, Chen Y, Chen Z, Xing Z.
Altern Ther Health Med. 2023 Oct;29(7):429-433.
Nanocarrier-based drug combination therapy for glioblastoma.
Zhao M, van Straten D, Broekman MLD, Préat V, Schiffelers RM.
Theranostics. 2020 Jan 1;10(3):1355-1372. doi: 10.7150/thno.38147. eCollection 2020.
Targeting AKT for cancer therapy.
Shariati M, Meric-Bernstam F.
Expert Opin Investig Drugs. 2019 Nov;28(11):977-988. doi: 10.1080/13543784.2019.1676726. Epub 2019 Oct 12.
KRAS G12C inhibitor combination therapies: current evidence and challenge.
Miyashita H, Kato S, Hong DS.
Front Oncol. 2024 May 2;14:1380584. doi: 10.3389/fonc.2024.1380584. eCollection 2024.
Advancements in combining targeted therapy and immunotherapy for colorectal cancer.
Singh M, Morris VK, Bandey IN, Hong DS, Kopetz S.
Trends Cancer. 2024 Jul;10(7):598-609. doi: 10.1016/j.trecan.2024.05.001. Epub 2024 May 31.
Recent progress in nanomedicine for enhanced cancer chemotherapy.
Wei G, Wang Y, Yang G, Wang Y, Ju R.
Theranostics. 2021 Apr 19;11(13):6370-6392. doi: 10.7150/thno.57828. eCollection 2021.
Exploiting temporal aspects of cancer immunotherapy.
Zemek RM, Anagnostou V, Pires da Silva I, Long GV, Lesterhuis WJ.
Nat Rev Cancer. 2024 Jul;24(7):480-497. doi: 10.1038/s41568-024-00699-2. Epub 2024 Jun 17.
